An Individualized Cancer Vaccine for Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2016
At a glance
- Drugs T-cell vaccine AlloVax (Primary) ; T-cell vaccine-AlloStim (Primary) ; Cisplatin; Fluorouracil
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Immunovative Therapies
- 10 Jul 2016 Planned End Date changed from 1 Dec 2018 to 1 May 2019.
- 10 Jul 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
- 10 Jul 2016 Planned initiation date changed from 1 Jul 2016 to 1 Dec 2016.